and inappropriate repair responses 4,5). In addition, functional changes in the chondrocytes, together with inflammatory cytokines such as interleukin-1 and tumor necrosis factor, may promote deterioration by inducing the expression of proteinases6-8). These proteinases include the matrix metalloproteinases (MMPs), members of a unique family of zinc-binding endopeptidases that are responsible for degradation of collagen, elastin, and other macromolecules in the extracellular matrix3,9). As expected from their degradative properties, the uncontrolled expression of MMPs has been reported to be associated with many pathological conditions involving the articular cartilage 3,10) Further, an important mechanism for the regulation of the activity of MMPs is via binding to a family of homologous proteins reffered to as the tissue inhibitors of metalloproteinases (TIMPs). The two-domain TIMPs are of relatively small size, and yet have been found to exhibit several biochemical and physiological / biological functions, including inhibition of active MMPs, pro MMP activation, cell growth promotion, matrix binding, inhibition of angiogenesis and the induction of apoptosis, whereas their controlled expression is essential for normal tissue remodeling and wound healing11). Glucocorticoids are frequently used for treatment of OA. Despite their therapeutic efficacy in modulating the clinical status of OA (especially in reducing pain), the influence of glucocorticoids on cartilage metabolism is not well defined9). Inflammation is a prominent clinical feature of OA, and its manifestations at affected joints include intense infiltration by inflammatory cells, swelling, and synovial effusion12-14), These inflammatory responses require alterations in the composition of the basement membrane, a process in which MMPs are involved. It has been established that synovial fibroblasts (SFs), in addition to chondrocytes, are important producers of MMPs3,9,10,15). Therefore, the present study was undertaken to examine the effects of the glucocorticoid dexamethasone (DEX) on MMP production by SFs in response to inflammatory stimulation.
Materials and Methods

Reagents
DEX was purchased from Sigma-Aldrich (St. Louis, MO) and was dissolved in RPMI-1640 medium (Sigma-Aldrich) supplemented with heat-inactivated 10% fetal calf serum (RPMI-FCS ; Irvine Scientific, Santa Ana, CA) at appropriate concentrations just before use. Lipopolysaccharide (LPS) extracted from Klebsiella pneumoniae was purchased from SigmaAldrich and dissolved in RPMI-FCS. Recombinant transforming growth factor-13 (TGF-13; R & D Systems, Dinarello, CA) was also dissolved in RPMI-FCS. Assays for MMP and tissue inhibitors of metalloproteinases (TIMP) MMP and TIMP concentrations in culture supernatants were determined by commercially available human MMP-1, -2, -3, -9, -13, TIMP-1 and TIMP-2 assay kits (Amersham Biosciences, Piscataway, NJ) according to the manufacturer's directions. The sensitivity of these ELISA kits was 1.7 ng / mL for MMP-1, 0.37 ng / mL for MMP-2, 0.6 ng / mL for MMP-3, 0.6 ng / mL for MMP-9, 0.094 ng / mL for MMP-13, 51.0 ng / mL for TIMP-1 and 3.0 ng / mL for TIMP-2. in the development and maintenance of OA and other diseases that are destructive to cartilage. Modulation of the ability of cells in joints to produce MMPs could therefore be of great value for treatment of OA. At present, little is known about the effects of glucocorticoids on MMP production, even though these drugs are frequently used in OA treatment9,10). MMPs comprise an enzyme superfamily of at least 21 members, which can be classified into subgroups of collagenases, stromelysins, gelatinases, membrane-type MMPs and other MMPs2,21). MMP-1 cleaves type I and II collagens, the most abundant proteins present in the osteoid layer, into characteristic 3 : 1 length fragments, which are subsequently dena- tured into random coiled polypeptide chains22). The digestion of type I and II collagens by MMP-1 thus appears to be the initial step of the entire bone resorption process. Subsequently, denatured collagen fragments can be degraded further by 2 gelatinases, MMP-2 and MMP-9. In contrast, MMP-3 has broad substrate specificity and can cleave other bone matrix proteins such as proteoglycans, glycoproteins and native collagen types IV, VII and IX in the osteoid layer. Together with these known actions of MMPs, the present results suggest that DEX decreases the ability of SF to produce MMPs under inflammatory stimulation, which thereby reduces degeneration of the osteoid layer covering the mineralized bone matrix. This should act to limit the destruction of joint cartilage and subchondral bone.
Source of cells
Apart from a pivotal role in cartilage degradation, MMPs enhance microvascular permeability24), which is responsible for edema and cell migration into the diseased area.
The attenuating effect of DEX on MMP production could therefore inhibit inflammatory cell infiltration into the synovial fluid, and reduce swelling or synovial effusion in the affected joints.
In addition to their inhibitory actions against MMP, TIMPs exert an inhibitory effect on the growth of fibroblasts25,26). Histological observation of OA joints has shown that fibrosis Fig. 4 develops on the surface of cartilage27). Our results showed a lack of effect of DEX on TIMP production, suggesting that administration of DEX into patients would not impair the actions of TIMP in suppressing the growth of fibroblasts in OA joints.
Together with the inhibition of MMP by TIMP, this would favorably modify the clinical condition of the affected joints. In conclusion, this study has clearly demonstrated that DEX acts not only against the degenerative joint disease symptoms of pain and inflammation but can also interfere with the collagenase activity that underlies the destruction of articular cartilage during OA. These effects may contribute, in part, to a favorable modification of the clinical status and quality of life for patients with OA. 
